Josh Kaufman

Optimization of an indazole series of selective estrogen receptor degraders: Tumor regression in a tamoxifen-resistant breast cancer xenograft.

Andiliy G. Lai, B. Darimont, J. Sensintaffar, 2015, Bioorganic & medicinal chemistry letters.

Selective estrogen receptor degraders with novel structural motifs induce regression in a tamoxifen-resistant breast cancer xenograft.

Andiliy G. Lai, B. Darimont, J. Sensintaffar, 2019, Bioorganic & medicinal chemistry letters.

The selective estrogen receptor downregulator GDC-0810 is efficacious in diverse models of ER+ breast cancer

K. Walter, Andiliy G. Lai, J. Giltnane, 2016, eLife.

Identification of GDC-0810 (ARN-810), an Orally Bioavailable Selective Estrogen Receptor Degrader (SERD) that Demonstrates Robust Activity in Tamoxifen-Resistant Breast Cancer Xenografts.

Andiliy G. Lai, B. Darimont, J. Sensintaffar, 2015, Journal of medicinal chemistry.

Maximizing ER-α Degradation Maximizes Activity in a Tamoxifen-Resistant Breast Cancer Model: Identification of GDC-0927.

Andiliy G. Lai, B. Darimont, J. Sensintaffar, 2018, ACS medicinal chemistry letters.

Identification of an Orally Bioavailable Chromene-Based Selective Estrogen Receptor Degrader (SERD) That Demonstrates Robust Activity in a Model of Tamoxifen-Resistant Breast Cancer.

Andiliy G. Lai, B. Darimont, J. Sensintaffar, 2018, Journal of medicinal chemistry.

Abstract 1648: Discovery and evolution of orally bioavailable selective estrogen receptor degraders for ER+ breast cancer: From GDC-0810 to GDC-0927

Jun Liang, A. Daemen, Andiliy G. Lai, 2018, Cancer Chemistry.